Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME)

Study Overview
=================
Brief Summary
-----------------
Standard treatment for oropharynx cancer is radiotherapy by intensity modulation with only one planification before treatment. Adaptative radiotherapy integrates one or several planifications during treatment radiotherapy in order to take into account anatomic modifications that occurs. Adaptative radiotherapy is very expensive, complex and is consuming human resources as well as equipment. ARTIX study (NCT01874587) entitled Phase III trial testing the benefit of intensity-modulated radiotherapy with weekly replanifications versus intensity modulated radiotherapy with only one planification in locally advanced oropharynx carcinoma for decreasing xerostomia is completed and clinical data from this study are used to analyse if xerostomia is decreased when adaptative radiotherapy is used. ARTOME study will assess cost-efficiency and cost utility between standard treatment (one pretherapeutic planification) and experimental treatment (weekly replanifications during treatment). Clinical data from ARTIX study will be used for ARTOME study.

Official Title
-----------------
Medico-economic Assessment of Adaptative Radiotherapy to Decrease Xerostomia in Locally Advanced Oropharynx Xerostomia

Conditions
-----------------
Oropharynx Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Locally advanced non-metastatic carcinoma of the oropharynx limited to T3 and T4 (whatever the N) and N2-N3 (whatever the T)(AJCC stage III-IV) Age ≥ 18 years and ≤ 75 years Performance status (WHO ≤ 2) Renal, hepatic and cardiovascular functions allowing systemic treatment administration Adapted stomatologic care Signed informed consent form Membership or beneficiary of a national insurance scheme Exclusion Criteria: Both parotids totally included in the target volume Stages T1 or T2 with positive node disease N1 Neoadjuvant chemotherapy Exereses of primitive tumor and/or nodes History of other cancer within 5 years (except for basocellular epithelioma and cervical) Previous neck radiotherapy Platinum salts, 5FluoroUracile (5FU) agents or cetuximab chemotherapy Unstable diseases (cardiovascular, renal, pulmonary, systemic lupus or sclerodermia) incompatible with study participation Patient participating in other therapeutic trial with experimental drug, 30 days before the inclusion. Patient already recruited in another biomedical research ( non interventional study is authorized) Pregnant or breast feeding patients Patient deprived of liberty, under tutorship, guardianship or placed under judicial protection Patient is deemed incapable of giving informed consent Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost utility analysis of standard radiotherapy (one pretherapeutic planification) compared to adaptative (weekly planification) | The cost utility analysis is expressed in cost per one year life gained | 2 years after end of radiotherapy treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adaptative radiotherapy, xerostomia, medico-economic assessment